摘要
目的:提高药物抗病毒疗效,降低其用量及毒副作用。方法:用薄膜法制备脂质体干扰素(L-IFN),用冻融法制备脂质体Ara-AMP(L-Ara-AMP)和ACV(L-ACV)。结果:经药物含量测定其包封率分别为43.2％、55％和35％。用病变抑制法测定,L-IFN抗病毒效价是未包封游离IPN的13倍,在加入胞壁酰二肽(MDP 10～100ng/ml)后,还可增效100倍。临床应用表明,100MU、300MU L-IPN及L-ACV总有效率分别为46.4％(14/30)、4/6、50％(6/12),而等剂量对照组(未包封)分别为14.3％(2/14)、33％(3/9)、25％。两组相比有显著性差异(P<0.05)。L-Ara-AMP 100mg剂量组疗效(37.5％),尚略高于未包封组200mg剂量组(28.5％)(P>0.05)。结论:脂质体可在一定程度上提高药物疗效,降低药物用量,是可取的增效方法。
Aim: In order to increase the efficacy of antiviral drugs, such as IFN, Ara-AMP,
ACV, and reduce their dosage, toxicity, and side effect. Methods: IFN, Ara-AMP, and ACV were encapsulated in liposomes with clinical observation made. IFN-liposomes were prepared with drymembrane method, and liposomes of Ara-AMP and ACV with modified frozen-thawing method. The antiviral activity of IFN was measured by inhibiting micro-pathology. Results: ①The encapsulated percentages of IFN, Ara-AMP, ACV are 43. 2%, 55%, and 35% respectively.②The antiviral activity of IFN-liposomes is thirteen fold as much as that of the free one, and it can be further increased to 100 times more when MDP at 10-100ng/ml added.③Clinical use indicates that the effective rates of 1MU, 3MU IFN and ACV in liposomes were 46. 4% , 66. 6% and 50% respectively. While those of the control group were 14. 3% , 33% and 25% respectively. The difference between the two groups is significant (P<0. 05). The effective rate of Ara-AMP liposomes at 100mg/day is also higher than that of the free one at 200mg/day (37. 5% v 28. 5%). Conclusion : The studies show that the liposomes can increase the efficacy of the antiviral action of IFN, Ara-AMP and ACV at certain degree or at least. They can also decrease the dosage and reduce the expense of them. So using liposomes to encapsulate antiviral drugs is a practical method to enhonce their efficacy.
出处
《中西医结合肝病杂志》
CAS
1997年第1期1-4,共4页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
基金
甘肃省科委资助课题
